Anaphylaxis to diphenylcyclopropenone during sensitization for wart treatment—A case report

Venkatesh, Kavya; Yun, James; Bakis-Petsoglou, Sophie

doi:10.1016/j.jdcr.2018.07.003

Cited by 7 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Topical DPCP is a type of contact immunotherapy mainly used in the treatment of alopecia areata recalcitrant viral warts [11]. According to previous reports, the cure rates of DPCP immunotherapy for viral warts ranged from 45 to 88% [12]. The mechanism of the action of immunotherapy for viral warts has been less thoroughly investigated.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Successful Treatment with Topical Diphenylcyclopropenone for Three Cases of Anogenital Warts in Children

Fujita

Mitsuishi

2019

Case Rep Dermatol

View full text Add to dashboard Cite

Anogenital warts are caused by human papillomavirus types 6 and 11. They are rare in children, and treatment is difficult since conventional treatments are generally painful and require the patient to be anesthetized. Topical diphenylcyclopropenone (DPCP) is a contact immunotherapy used for treatments of recalcitrant warts and alopecia areata. We herein report 3 cases of anogenital warts in children successfully treated with topical DPCP. Our results suggest that topical DPCP may be a valuable option for the treatment of anogenital warts in children who have difficulty with painful destructive therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

“…DPCP forms hapten with wart proteins. This DPCP hapten is recognized by T cells, eventually resulting in the wart's destruction [12, 13]. Our patients were previously treated with cryotherapy or topical application of 5% imiquimod cream, but without any result.…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment with Topical Diphenylcyclopropenone for Three Cases of Anogenital Warts in Children

Fujita

Mitsuishi

2019

Case Rep Dermatol

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

“…A vesicular response or more significant reactions imply higher sensitivity to the treatment, and the patient was instructed to apply topical steroid cream and excluded from the study for fear of anaphylaxis. 20 b) Elicitation phase. After sensitization, according to the patient's capacity to trigger a modest inflammatory response, we began therapy with a weekly application of DPCP solutions ranging between 0.001% and 1%.…”

Section: Treatmentmentioning

confidence: 99%

Effectiveness and safety of topical application of diphenylcyclopropenone versus podophyllin in treatment of genital warts

Halim

Ahmed²,

Eyada

2023

Int J STD AIDS

View full text Add to dashboard Cite

Background Many therapeutic modalities are available for treating genital warts; however, the effectiveness of both diphenylcyclopropenone and podophyllin is still controversial. Aim To evaluate the effectiveness and safety of diphenylcyclopropenone and podophyllin in treating genital warts. Methods This study included 57 patients, divided randomly into two groups. Group (A): diphenylcyclopropenone ( n = 29). Group (B): podophyllin 25% ( n = 28). In group (A), sensitization was done with 2% diphenylcyclopropenone. Then, after 1 or 2 weeks, treatment started with a weekly application of diphenylcyclopropenone solutions ranging between 0.001 and 1% until clearance, or for a maximum of 10 sessions. In group (B), podophyllin 25% was applied weekly until clearance or for a maximum of 6 weeks. Results Higher clearance was achieved in group A, with 19 of 29 (65.5%) patients, than in group B, with 9 of 28 (32.1%) ( p-value = 0.004). Also, effectiveness increases with young age in group A. Shorter wart duration was associated with better response in both groups ( p-value = 0.005). No serious adverse effects occurred in either group. No recurrence was detected in group A, while seven patients (77.8%) had recurrence in group B after 1 year of follow up. Conclusion Diphenylcyclopropenone shows a higher success rate than podophyllin in treating genital warts and a lower recurrence rate.

show abstract

“…Except for the expected adverse reactions, that is, contact dermatitis [ 148 , 163 – 165 ] or lymphadenopathy [ 166 – 168 ], there are some rare or even serious adverse events reported. These include urticaria [ 169 – 177 ], depigmentation [ 155 , 156 , 160 ], vitiligo [ 150 – 154 , 157 – 159 , 178 ], erythema multiforme [ 179 – 183 ], discoid lupus erythematosus [ 184 , 185 ], angioedema [ 186 , 187 ], nickel sensitivity [ 188 ], allergic contact dermatitis from dyes in wigs [ 189 ], acquired hair curling [ 190 ], hair pigmentary changes [ 191 ], psoriatic koebnerization [ 192 ], pityriasis lichenoides [ 193 ], dyspepsia [ 173 ], epidermolysis bullosa acquisita [ 194 ], and anaphylaxis [ 195 ]. In addition, there are a few reports documenting sensitization to the medical staff that handle the chemical compound [ 196 – 201 ].…”

Section: Adverse Effects and Safety Concerns Of Topical Immunotherapymentioning

confidence: 99%

Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata

Lai

Tsai

2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

For decades, contact immunotherapy with dinitrochlorobenzene, diphencyprone, and squaric acid dibutylester has played an important role in both clinical practice and scientific research. It is listed as the first-line treatment for extensive alopecia areata and was more recently approved for melanoma treatment as an orphan drug in the USA. Moreover, owing to the relative low cost and safety, topical immunotherapy has also been used in many infectious, neoplastic, and inflammatory dermatological diseases. It is especially valuable in vulnerable groups, for cosmetic/pain sensitive areas, or for multiple lesions. In this review, we summarize the current evidence supporting the use of contact immunotherapy for treatment of skin diseases, from articles collected from PubMed database. Owing to space limitation and already numerous studies focusing on alopecia areata, we include only skin diseases other than alopecia areata. In addition to diseases that have been reported to be treated by contact immunotherapy, the hypothesized mechanism, prognosis prediction, efficacy, and safety of these topical agents are discussed.

show abstract

Anaphylaxis to diphenylcyclopropenone during sensitization for wart treatment—A case report

Cited by 7 publications

References 10 publications

Successful Treatment with Topical Diphenylcyclopropenone for Three Cases of Anogenital Warts in Children

Successful Treatment with Topical Diphenylcyclopropenone for Three Cases of Anogenital Warts in Children

Effectiveness and safety of topical application of diphenylcyclopropenone versus podophyllin in treatment of genital warts

Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata

Contact Info

Product

Resources

About